bioMérieux – Business review for the nine months ended

30 September, 2018

  • Strong sales dynamic confirmed in third quarter, with an 8.8% increase in organic sales
  • Growth of 9.8% at constant exchange rates and scope of consolidation over the nine months ended September 30:
    • €1,749 million in sales
    • Up 4.5% as reported
  • Ramp-up in business on the back of three key growth drivers: molecular biology with the BIOFIRE® product line, activity in the Asia Pacific region, and industrial applications.

Alexandre Mérieux, Chairman and Chief Executive Officer, said: “bioMérieux delivered another robust sales performance in the third quarter of 2018, with organic growth nearing 9%. These positive dynamics place the Group on track to achieving its financial objectives for the year.


 

Diagnostics is power